Is Retatrutide a GLP-1?

Short answer: Retatrutide is more than a GLP-1. It is a "triple agonist" (a molecule that switches on three different targets at once). It acts on the GLP-1 receptor and two others as well: the GIP receptor and the glucagon receptor. A pure GLP-1 compound, like semaglutide, switches on just one receptor. Retatrutide switches on three.

So when people ask "is reta a GLP-1?" the honest answer is: yes and no. Yes, the GLP-1 receptor is one of its three targets. But no, it is not only a GLP-1 — calling it a plain GLP-1 misses two-thirds of what it does. The rest of this guide explains, in plain English, exactly what each of those receptors is and why researchers study a molecule that hits all three.

First, what is a GLP-1?

GLP-1 is short for "glucagon-like peptide-1". It is a natural hormone (a chemical messenger your body makes) that comes mostly from the gut. A hormone like this travels around and passes messages to cells. To understand the rest of this guide, you only need three plain-English words: receptor, agonist, and GLP-1.

A receptor is a docking point on the outside of a cell — picture it as a lock. A cell can have many different locks, and each lock only responds to the right shape of key. An agonist is a molecule that fits one of those locks and switches it on — picture it as a key that turns the lock to the "on" position. So when researchers say a molecule is a "GLP-1 receptor agonist", they simply mean it is a key shaped to fit the GLP-1 lock and switch it on.

The diagram below shows the idea. This is the single most useful picture for the whole topic, so it is worth a careful look: the key (agonist) slides into the lock (receptor) that sits on the cell surface, and the lock flips to "on".

So a "GLP-1" in the everyday sense usually means a GLP-1 receptor agonist: a key built to fit and switch on the GLP-1 lock. Semaglutide is the best-known example — it is a key shaped for just that one lock. Hold onto that idea, because the question "is Retatrutide a GLP-1?" is really asking: does Retatrutide only fit the GLP-1 lock, or does it fit more locks than that?

So is Retatrutide a GLP-1 receptor agonist?

Yes — partly. Retatrutide really does switch on the GLP-1 receptor. The GLP-1 lock is one of its targets, so it is fair to say it has GLP-1 receptor agonist activity built in. If that were the only lock it fit, you could call it "a GLP-1" and stop there.

But it does not stop there. Retatrutide is built so the same single molecule fits three different locks, not one. That is the key difference between Retatrutide and a pure GLP-1 like semaglutide. Both fit the GLP-1 lock; only Retatrutide also fits the other two. So the most accurate label is not "a GLP-1" but "a GLP-1 / GIP / glucagon triple agonist" — GLP-1 is just the first of three.

What makes Retatrutide a triple agonist

A triple agonist is a molecule that switches on three receptor locks at once. Retatrutide (also called LY3437943, made by the pharmaceutical company Eli Lilly) is built to fit three locks that all sit in the body's metabolism machinery (metabolism is just the way the body handles energy, sugar, and fat). Here is each lock in one plain sentence, framed as what researchers study it for — not as anything it does in people:

• GLP-1 receptor (glucagon-like peptide-1) — in metabolism research this lock is studied for its part in blood-sugar signalling and the release of insulin (the hormone that lowers blood sugar).
• GIP receptor (glucose-dependent insulinotropic polypeptide — a long name for another gut hormone) — in research this lock is studied for its part in how insulin is released and how fat tissue handles energy.
• Glucagon receptor — in research this lock is studied for its part in how the liver releases stored sugar and how much energy the body burns.

The diagram below shows the whole idea at a glance: one molecule of Retatrutide in the middle, with arrows fanning out to all three receptor locks. For contrast it also shows that semaglutide reaches just one lock and tirzepatide reaches two.

In short: switching on one lock makes a single agonist, switching on two makes a dual agonist, and switching on three makes a triple agonist. Retatrutide is in that third group — which is exactly why "is reta a GLP-1?" is too small a question. The GLP-1 lock is only one of its three.

Retatrutide vs semaglutide vs tirzepatide (how many receptors?)

The simplest way to see where Retatrutide sits is to count locks. The table below lines up the three best-known compounds in this family and shows how many receptors each one switches on.

So all three are "GLP-1s" in the narrow sense that all three fit the GLP-1 lock. But only Retatrutide also fits the GIP and glucagon locks. For a deeper side-by-side, see our full Retatrutide vs Tirzepatide vs Semaglutide comparison.

Is Retatrutide the same as Ozempic or Mounjaro?

No. Ozempic and Mounjaro are brand names for licensed medicines (Ozempic contains semaglutide; Mounjaro contains tirzepatide). They have been reviewed and approved by medicine regulators and are prescribed by doctors. Retatrutide is a different thing entirely.

Retatrutide (also called LY3437943, from Eli Lilly) is an investigational compound — meaning it is still being studied and has not been approved as a medicine. Velox Peptides supplies it strictly as a research reagent for in vitro lab use (work done in test tubes, dishes and lab equipment — not in people). It is not a medicine, not a brand-name product, and not for human use. So Retatrutide is neither Ozempic nor Mounjaro, and it is not a swap for either.

Is Retatrutide a peptide?

Yes. Retatrutide is a synthetic peptide — a lab-made short chain of amino acids (amino acids are the small building blocks that join together to form proteins). A peptide is just a short version of that chain. Because it is built this way, it can be shaped precisely to fit those three receptor locks.

Velox Peptides supplies it as a lyophilised (freeze-dried) powder, which keeps it stable for storage and shipping. It is HPLC-verified at ≥99% purity (HPLC is a standard lab test that measures how pure a sample is) and comes with a Certificate of Analysis (a document confirming the test results). You can see the full specification on the Retatrutide product page, and any unfamiliar terms here are explained in our research glossary.

Why researchers study triple agonists

The interesting research question behind a triple agonist is simple to state: what happens when you switch on all three locks together, instead of one or two? Each of the GLP-1, GIP and glucagon pathways has been studied for years on its own, and in pairs. A triple agonist lets scientists study how the three pathways interact — whether they add up, cancel out, or work together in unexpected ways. That is a basic-science question about receptor signalling, studied in lab models, not a claim about any outcome in people.

Retatrutide is a useful tool for this kind of work partly because it is unusually well documented. It has appeared in Phase 1 and Phase 2 research trials (early-stage studies carried out in careful steps), with findings published in major journals including the New England Journal of Medicine, The Lancet, and Cell Metabolism.[1][2][3] Everything in those papers is a research observation about the compound and its pathways — Velox makes no claims about effects in people and supplies Retatrutide for in vitro research use only.

Frequently Asked Questions